1% to 7% in NSCLC, 4, 6, 9, 10 and, together, these rearrangements can be identified in approximately 5%-9% of NSCLC. 7, 11, 12 Lung cancers harboring these fusion genes show oncogene addiction to the respective fusion genes and are therefore sensitive to treatment with tyrosine kinase inhibitors (TKI), such as crizotinib, alectinib (CH5424802), and ceritinib (LDK378).
Fluorescence in situ hybridization, immunohistochemistry (IHC), and real-time PCR can be used to detect fusion genes in clinical tissue samples. The FISH break-apart assay is the gold standard for companion diagnosis. Development of the above-mentioned agents 8, 9, 13 has driven a rapid need for systematic and sensitive assays to de- 
| MATERIAL S AND ME THODS

| Samples
A total of 160 lung cancer samples were collected from Tokyo
Medical University Hospital and Kindai University Hospital. All the samples were from resections that had been formalin-fixed and par- 
| Detection of fusions
Total RNA was reverse transcribed using the SuperScript VILO cDNA Synthesis Kit (Life Technologies Japan, Tokyo, Japan) followed by library preparation using ODxFT (Life Technologies Japan).
Reverse-transcribed cDNA was amplified using the supplied reagent. The PCR product was digested and ligated with a barcode adaptor followed by purification (all from supplied reagent). The purified libraries were quantified using the Ion Library TaqMan
Quantitation Kit (Life Technologies Japan), followed by a pooled and prepared sequencing template using the Ion OneTouch Dx Template TA B L E 1 Partners for ALK, RET, ROS1, and NTRK1 Data analysis was carried out using an Ion Torrent T430 Server.
This assay determined the fusion gene to be positive if the detection of the fused sequence was greater than the cutoff value.
| Fluorescence in situ hybridization
Formalin-fixed and paraffin-embedded tissues sectioned at a thickness of 4 μm and placed on glass slides were subjected to FISH using 
| Statistical analysis
The kappa statistic and associated 95% confidence intervals were used to measure agreement among the assays.
| RE SULTS
| Method correlation agreement analysis for the detection of ALK fusion transcripts
Of the 150 clinical research samples tested, 149 (99.3%) passed the quality control requirement. One failure case could not be analyzed using ODxFT because of the low yield of library.
ALK fusion genes were detected in 11/149 (7.4%) and 12/150 (8.0%) samples using ODxFT and ALK-FISH, respectively ( Detailed findings for all the clinical samples are shown in Table S1 .
Representative FISH data and Integrative Genomics Viewer (IGV) diagram from ALK-positive samples are shown in Figure 1A .
| Detection of ROS1 and RET fusion transcripts
Oncomine 
| D ISCUSS I ON
In the present study, we showed the feasibility of using the ODxFT assay to detect fusion genes in lung cancer tissues with a high rate of success. Discordance between ALK FISH and other methods has been previously reported. 14, 15 A recent study using the Ion AmpliSeq RNA Lung Cancer Research Fusion Panel for fusion detection reported 100% concordance between this method and other methodologies. 16 This study and ours confirm the clinical performance of inhouse NGS tests using RNA samples obtained from small tissue samples. IHC staining offers a cheaper alternative; however, this methodology is subjective, and accurate interpretations are sometimes difficult. 17 An RT-PCR kit to detect ROS1 fusions is available as a companion diagnosis. The main limitation of traditional RT-PCR is that this method typically focuses on only the most common fusion events and is thus limited when it comes to detecting rarer exon combinations and is unable to detect fusions involving novel 5′ partners. 18 In contrast to FISH or IHC, detection of ALK, RET, ROS1, and NTRK1 fusions can be combined into a single assay using ODxFT. This allows the detection of fusions that might otherwise remain undetected.
TA B L E 2 Constitution of subtypes
Fusion genes No. of subtypes
EML4-ALK 18
KIF5B-RET 7
KIF5B-ALK 4
SDC4-ROS1 4
SLC34A2-ROS1 4
CD74-ROS1 2
GOPC-ROS1 2
HIP1-ALK 2
MPRIP-NTRK1
In the present study, we had one case with sequencing failure (K013) and one case discordant with FISH analysis (T060). Sample ODxFT assay addresses this problem in two ways. First, during the analysis of the sequenced reads, all reads that are initially unaligned to the reference sequence are split in half and allowed to realign.
This step fosters the detection of novel fusions involving existing primers. Second, the assay includes a method for detecting fusions involving unknown partners using a 3′/5′ imbalance calculation. This step analyzes the expression levels of the 3′ and 5′ ends of each driver gene. For genes involved in a fusion event, the 3′ end of the gene is now under different regulatory control and typically shows overexpression relative to the 5′ end of the gene. Another recently described methodology using NanoString technology also exploits this phenomenon of 3′ overexpression. 20 They found that looking at the imbalance between 3′ and 5′ expression works relatively well for ALK and RET, which are normally not expressed in lung tissue, but this calculation was more difficult for ROS1, as this gene is normally expressed at high levels. Therefore, in the process of developing this panel as an IVD (in vitro diagnostics), the use of 3′/5′ expression imbalance was resigned
Oncomine Dx Fusion Transcript Test is focused on fusion genes using RNA materials obtained from FFPE tissue. In the present study, only samples that did not contain an epidermal growth factor receptor (EGFR) gene mutation were examined. In clinical practice, for Japanese lung cancer patients, EGFR gene mutation testing is the first gene screening test that is carried out because the prevalence of EGFR gene mutation positivity is relatively high (40%-50%). Therefore, it is reasonable to screen for fusion genes in a single assay using ODxFT after the confirmation of a wild-type EGFR genotype.
In conclusion, the RT-PCR NGS assay described here offers many advantages for laboratory testing in lung adenocarcinoma samples.
The single-assay format potentially allows for a faster turnaround time and a lower cost than carrying out the assays separately.
Furthermore, the small amount of input RNA that is required is very advantageous for this type of sample. However, ODxFT primarily targets known fusion genes. Last, efforts to periodically update the primer pool as additional partner genes for ALK, ROS1, RET, and NTRK1 fusions are identified would aid in the continuing utility of this assay.
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